Literature DB >> 6381742

Cancer chemotherapy: past, present, and future--Part I.

J C Wright.   

Abstract

Cancer is of major concern today because of its high mortality. It is estimated that 66 million people in this country will eventually develop cancer; 1983 estimates were 855,000 new cases and 440,000 deaths from cancer.Because of limitations of surgery and radiation therapy in effecting a cure for cancer, chemotherapy has become increasingly important. The developments in the chemical control of cancer in man are encouraging.This two-part paper covers the historical milestones in the development of the chemical and hormonal control of cancer, present successes with the use of polychemotherapy, and the hopeful trends in research. Part II will be published in a future issue of this journal.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6381742      PMCID: PMC2609825     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  64 in total

1.  OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.

Authors:  J C WRIGHT; M M LYONS; D G WALKER; F M GOLOMB; S L GUMPORT; T J MEDREK
Journal:  Cancer       Date:  1964-08       Impact factor: 6.860

2.  Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit.

Authors:  O CREECH; E T KREMENTZ; R F RYAN; J N WINBLAD
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

3.  Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine.

Authors:  H E KAUFMAN
Journal:  Proc Soc Exp Biol Med       Date:  1962-02

4.  Clinical management of advanced gastrointestinal cancer.

Authors:  C G Moertel
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

5.  Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use.

Authors:  D A KARNOFSKY; J H BURCHENAL; G C ARMISTEAD; C M SOUTHAM; J L BERNSTEIN; L F CRAVER; C P RHOADS
Journal:  AMA Arch Intern Med       Date:  1951-04

6.  Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin.

Authors:  I M Murray-Lyon; A L Eddleston; R Williams; M Brown; B M Hogbin; A Bennett; J C Edwards; K W Taylor
Journal:  Lancet       Date:  1968-10-26       Impact factor: 79.321

7.  Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

Authors:  N I Nissen; V Larsen; H Pedersen; K Thomsen
Journal:  Cancer Chemother Rep       Date:  1972-12

8.  Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors.

Authors:  I M Ariel
Journal:  Cancer       Date:  1970-03       Impact factor: 6.860

9.  Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.

Authors:  R O Johnson; G Metter; W Wilson; G Hill; E Krementz
Journal:  Cancer Treat Rep       Date:  1976-02

10.  Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia.

Authors:  H SHAY; C ZARAFONETIS; N SMITH; I WOLDOW; D C SUN
Journal:  AMA Arch Intern Med       Date:  1953-11
View more
  4 in total

Review 1.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

2.  Update in cancer chemotherapy: general considerations and breast cancer, Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-08       Impact factor: 1.798

Review 3.  Personalized Cancer Models for Target Discovery and Precision Medicine.

Authors:  Carla Grandori; Christopher J Kemp
Journal:  Trends Cancer       Date:  2018-08-08

Review 4.  Update in cancer chemotherapy: genitourinary tract cancer, Part 2: Wilms' tumor and bladder cancer.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-02       Impact factor: 1.798

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.